drugset / Trial / NCT05707325
Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an investigator-initiated trial aimed at evaluating the safety and preliminary efficacy of a novel red blood cell-based therapy, where engineered red blood cells are conjugated with checkpoint inhibitors.
Timeline
- Start
- 2023-01-16
- Primary completion
- 2025-12-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | engineered red blood cell | Cell therapy | 1e+11 cells | — |
| Subject | engineered red blood cell | Cell therapy | 2e+11 cells | — |
| Subject | engineered red blood cell | Cell therapy | 3e+11 cells | — |
| Subject | engineered red blood cell | Cell therapy | 3.5e+11 cells | — |